{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_18512", "batch_size": 200, "batch_pos": 22, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain a high-potency verb, potent metaphor, critical alert phrase, or superlative/intensifier + harm noun.", "method": "llm_batch", "batch_id": "batch_2_11352", "batch_size": 200, "batch_pos": 191, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 3, "answer": "no", "rationale": "The segment contains numbers ('665,000 doses', '40 million vaccines', 'four years') but no moderate verb from the Q3 list.", "method": "llm_batch", "batch_id": "batch_3_15268", "batch_size": 200, "batch_pos": 155, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_16396", "batch_size": 200, "batch_pos": 153, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 5, "answer": "no", "rationale": "The segment reports deal details without explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_15040", "batch_size": 200, "batch_pos": 150, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_1168", "batch_size": 200, "batch_pos": 121, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_17176", "batch_size": 200, "batch_pos": 110, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 8, "answer": "yes", "rationale": "The segment states 'The deal secures up to 665,000 doses... and includes an option for a further 40 million vaccines', describing a capability/resource without active reassurance.", "method": "llm_batch", "batch_id": "batch_8_17584", "batch_size": 200, "batch_pos": 185, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
